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based cross sectional analysis. European Quality of Life scale (EQ-5D) was used for
assessment of HRQoL. Registered Hepatitis B patients aging 18 years and above
were approached. Descriptive statistics were used to describe demographic and
disease related characteristics of the patients. Percentages and frequencies were
used to categorize the categorical variables, while means and standard deviations
were calculated for the continuous variables. Non paramatric tests (Mann-Whitney
and Kruskal Wallis test) were used where appropriate. HRQoL was scored by using
values from UK general population survey. All analyses were performed using SPSS
16.0. RESULTS: Three hundred ninety hepatitis B Patients were enrolled in the
study with 232 (59.5%) of males. Majority (n126, 32.3%) were categorized in age
group of 18-30 years. HRQoL was measured poor in our study patients (0.3498
0.31785) with Visual Analogue Scale score of 59.1510.517. Among all variables,
only gender had significant relation with HRQoL score. CONCLUSIONS: Hepatitis B
has an adverse impact of on patients’ well-being and HRQoL. Patient centric efforts
are recommended to improve patients HRQoL with Hepatitis B.
PIN95
THE IMPACT OF INFLUENZA ON IN- AND OUTPATIENTS’ HEALTH RELATED
QUALITY OF LIFE DURING THE PANDEMIC SEASON 2009-2010 IN SPAIN
Garin O1, Hollmann M1, Galante M1, Ferrer M2, Garcia-Altés A3, Sicuri E1, Nebot M1,
Dominguez À1, Alonso J2
1CIBERESP, Barcelona, Spain, 2IMIM-Research Institute Hospital del Mar, Barcelona, Spain,
3Catalan Agency for Health Information, Assessment and Quality (CAHIAQ), Barcelona, Spain
OBJECTIVES: The aim of this study was to estimate the impact on HRQL of in- and
outpatients with confirmed Influenza A H1N1/2009, and estimate the associated
burden during the pandemic season 2009-2010. METHODS: Longitudinal, observa-
tional, multi-centre study of in- and outpatients with confirmed diagnosis of influ-
enza A H1N1/2009 in Spain. Baseline sociodemographic and clinical characteristics
and HRQL were assessed at the hospitalization or primary care visit recruitment.
HRQL in the previous 7 days was also assessed. A sub-sample of patients was
followed-up after recovery. The EQ-5D was used to describe HRQL and calculate
utilities. HRQL loss was evaluated among in- and outpatients by several character-
istics. Loss of Quality Adjusted Life Years (QALYs) was calculated at individual level
taking into account the length of the influenza syndrome. Global burden was esti-
mated from the total number of cases in Spain. RESULTS: A total of 432 inpatients
and 563 outpatients were included and 145 and 184, respectively, were followed-
up. EQ-5D index previous to influenza was 0.81 (CI95% 0.78–0.84) for inpatients and
0.93 (CI95% 0.91–0.94) for outpatients. During influenza, HRQL loss was -0.58(0.02)
for inpatients, and -0.43(0.02) for outpatients. For all patients, Pain/discomfort and
Usual Activities were the most affected dimensions presenting a deterioration
from 73% to 80%. The individual QALYs loss for inpatients was 0.0135 and for
outpatients, 0.0098. In contrasts, the global burden was 41 (inpatients) and 7,283
QALYs (outpatients). CONCLUSIONS: Influenza H1N1/2009 supposed a significant,
but transient, impact on patients HRQL. The pandemic produced a considerable
QALYs loss, especially among less severe patients, comparable with the burden of
some chronic diseases and higher than that of other infectious diseases.
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OBJECTIVES:There is growing evidence in the literature supporting the association
between tobacco smoking and poor tuberculosis (TB) treatment outcomes. Con-
necting TB and tobacco cessation interventions has been strongly advocated as this
may produce significant benefits. However, no study has documented the impact
of such integration on health-related quality of life (HRQoL). The objective of the
study was to document the impact of an integrated TB directly observed therapy
short-course (DOTS) plus smoking cessation intervention (SCI) on HRQoL.
METHODS: This was a non-randomized controlled study (quasi experimental de-
sign) involving 120 TB patients who were current smokers at the time of TB diag-
nosis. Patients were assigned to either of two groups: conventional TB-DOTS plus
smoking cessation intervention (SCIDOTS group) or conventional TB-DOTS only
(DOTS group). The effects of the novel intervention on HRQoL were measured using
EQ-5D questionnaire. Two-way repeated measure ANOVA was used to examine
the effects. RESULTS: When compared, participants who received the integrated
intervention had a better HRQoL than those who received the conventional TB care.
The SCIDOTS group had a significantly greater increase in EQ-5D utility score than
the DOTS group during 6 months follow-up (mean SD 0.98 0.08 vs. 0.91 0.14,
p  0.006). Similarly, the mean scores for EQ-VAS showed a consistently similar
trend as the EQ-5D indices, with the scores increasing over the course of TB treat-
ment. Furthermore, for the EQ-VAS, there were significant main effects for group [F
(1, 84)  4.91, p  0.029, 2  0.06], time [F (2, 168)  139.50, p  0.001, 2  0.62]
and group x time interaction [F (2, 168)  13.89, p  0.001, 2  0.14].
CONCLUSIONS: This study provides evidence that an integrated TB-tobacco treat-
ment strategy could potentially improve overall quality of life outcomes among TB
patients who are smokers.
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OBJECTIVES: Health-related quality of life (HRQL) is modulated by the type and
frequency of symptoms experienced in daily life. Such a relationship is likely de-
termined in part by treatment regimen and health care system. We studied how
symptoms reported by HIV patients under PI- vs. NNTI-based HAART relate to
different HRQL dimensions on the PROQOL-HIV questionnaire. METHODS: N424
HAART patients (4110 yrs., 36% females, 8 countries), without comorbidity, com-
pleted a 31-symptom HIV checklist (presence/absence) and the PROQOL-HIV ques-
tionnaire (43 Likert items, 8 dimensions). Hierarchical cluster analysis uncovered
the structure of symptoms experienced in patients under PI (N242) or NNTI
(N182) regimen. Canonical correlation analysis (CCA) showed the relationships
between symptoms and HRQL dimensions, and between-country variations.
RESULTS: A common group of symptoms related to body fat (lipodystrophy) and
weight changes was shared by patients across treatment regimens. However, fre-
quency of some side-effects–sleep disturbance, headache, diarrhea, nausea, fa-
tigue and pain–were more frequent with PI regimens. The CCA showed that a) body
fat change, sleep disturbance, skin problems and abdominal pain symptoms were
related to the ‘body change’ and ‘physical health and symptoms’ HRQL dimensions
(canonical correlation, 0.78), and b) symptoms concerning physical appearance
were related to the ‘stigma’ dimension, whereas other side-effects did not. It also
replicated a common finding whereby patients from Western countries (France,
Australia, USA) tend to report better HRQL compared to Chinese and Cambodian
patients, the latter also experiencing more symptoms due to IP-based treatment.
CONCLUSIONS: Treatment-related symptoms aligned with PROQOL-HIV dimen-
sions and known differences between countries. The use of CCA as an exploratory
multiple endpoints model helped to unravel complex relationships between symp-
toms and HRQL facets. The choice of treatment strategies should rely not only on
symptoms experience, but also account for their relations to HRQL in light of vary-
ing access to care.
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OBJECTIVES:New protease inhibitors (PIs) significantly improve sustained virolog-
ical responses (SVRs) in patients with genotype 1 chronic hepatitis C. However,
treatment (Tx) in prior null-responders with advanced fibrosis often results in
failure to achieve SVR and development of resistant mutations. Emerging quadru-
ple Tx adding two direct antiviral agents may achieve SVR in nearly all of these
patients. This study aimed to compare two strategies: 1) treating prior null-re-
sponders with fibrosis stage 3 (F3) or stage 4 (F4) with telaprevir  peginterferon 
ribavirin (“TPR strategy”) versus 2) withholding Tx until more effective antiviral
agents become available (“Wait strategy”). METHODS: The MONARCH Hepatitis C
cost-effectiveness model was used to project outcomes in cohorts of 55-year-old
prior null-responders using published dynamic transition rates for disease pro-
gression. “TPR strategy” achieves SVR in 42% of F3 and in 14% of F4 patients. In
the Wait strategy, patients would wait for 5 years and then initiate quadruple Tx
yielding 90% SVR. Quadruple Tx would be used as rescue in patients failing
“TPR”, 70% of whom would harbor virus resistant to PIs. Patient outcome in
terms of SVR and quality-adjusted-life years (QALYs) were assessed 10 years there-
after. Benefits were discounted at 3.5%. RESULTS: Projected SVR rates were higher
with the “Wait strategy” (76% and 65% for F3 and F4 respectively) than “TPR
strategy” (50% and 30% for F3 and F4 respectively). Per-patient expected QALYs
were higher for “Wait strategy” than “TPR strategy”; 8.59 versus 8.47 QALYs in
F3 patients and 7.5 versus 6.7 QALYs in F4 patients. The Wait strategy was asso-
ciated with one-third fewer re-treatments. CONCLUSIONS:Waiting for future qua-
druple antiviral therapy maximized the predicted health benefit both in terms of
response (SVR) and QALYs; furthermore, the reduction in re-treatments associated
with the Wait strategy is noteworthy given the likely high cost of triple therapy.
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OBJECTIVES: To investigate the optimal pertussis booster vaccination strategy for
the The Netherlands and to explore the impact of different assumptions for pa-
rameters surrounded by uncertainty. METHODS: The authors designed a realistic
age-structured deterministic model. Assuming a steady state situation and cor-
recting for underreporting, the model was calibrated using notification data from
the period 1996-2000. Several sensitivity analyses were performed including vary-
ing the age of a booster dose (or multiple booster doses), expected vaccine uptake,
duration of protection after natural infection, underreporting factors, contact func-
tion, and transmission probabilities. RESULTS: The results indicated that the op-
timal age of an additional booster dose is in the range of 10-15 years, and imple-
mentation of this booster dose will reduce both symptomatic and asymptomatic
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infections, although the incidence of symptomatic infections in the older age
classes does increase. The impact of the different assumptions used in the model
was in general limited. CONCLUSIONS: We conclude that over a wide range of
assumptions, an additional booster dose can reduce the incidence of pertussis in
the population.
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OBJECTIVES: To investigate doctors’ perceptions towards factors underlying irra-
tional prescribing practices in treatment of malaria in Pakistan.METHODS:A qual-
itative study with snowball sampling technique was used to identify nineteen
doctors working at hospitals in Islamabad and Rawalpindi. Semi-structured inter-
views were conducted with the doctors until the point of saturation was obtained.
The interviews, which were audio-taped and transcribed verbatim, were evaluated
by thematic content analysis and by other authors’ analysis. RESULTS: Thematic
content analysis identified three major themes and several subthemes: 1) Factors
responsible for irrational prescribing practices in treatment of malaria; 2) Lack of
implementation of standard malaria treatment guidelines in the country; and 3)
Strategies to improve irrational prescribing practices in treatment of malaria. All
the doctors agreed on lack of implementation of standard guidelines in treatment
of malaria while mixed responses were observed regarding factors influencing
rational prescribing. Influence of pharmaceutical industry and unsupervised poly-
therapy were cited as major determinants for irrational prescribing practices in
case of malaria. CONCLUSIONS: The findings suggest that the doctors in Pakistan
are aware of irrational prescribing practices and its consequences in treatment of
malaria but are facing significant barriers in terms of improving the current pre-
scribing practices. There is an urgent need to design strategies such as implemen-
tation of standard malaria treatment guidelines, revision of health policies and up
gradation of education and training of health players in order to improve the cur-
rent prescribing practices for antimalarials.
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OBJECTIVES: Every winter season an influenza epidemic occurs, although strength
and duration may vary. In 2006-2007 in Austria presumably 5% of the whole pop-
ulation fell sick while 21% of age 15 and above were vaccinated. The goal was to
build an agent based model to understand, model and simulate the progress of
influenza epidemics. METHODS: The agent based model simulates single persons
with an infection state (susceptible, infected with or without symptoms, resistant,
vaccinated). Based on the results of a wide European study (POLYMOD, EC-Project
SP22-CT-2004-502084) people have contacts in different places like housholds,
schools or workplaces. Transmissions are possible upon contacts, then a person is
infected for a while until he or she becomes resistant upon recovery. RESULTS: The
outbreak of the epidemic starts when a few people are initially infected while the
rest is susceptible or vaccinated. After some time the epidemic stops due to a larger
number of resistant and a smaller number of susceptible people. Since only 5% of
the population fall sick the situations at outbreak and at termination of the epi-
demic are similar and therefore it behaves very sensitive to parameter changes.
CONCLUSIONS: Some parameter changes in the model can be interpreted as inter-
ventions in reality. But usually the influenza does not react sensitive to interven-
tions. For example, an increase of the vaccination rate by 5% prevents an outbreak
of the epidemic in the model which is obviously not true. This insight has two
consequences: First, the influenza does not just spread and stop by transmission
and recovery of people. There must be one or more other impacts modulating
outbreaks like predestined people to fall sick or the climate. Second, without
knowledge of these impacts it is almost impossible to predict the effect of vacci-
nation strategies exactely.
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OBJECTIVES: In 1996, the Brazilian government implemented a universal access
program for anti-retroviral drugs to improve the treatment of HIV/AIDS. A recent
study showed $1.78 billion USD savings from the program compared to pricing in
the US. This study estimates the drug costs saved in 2010 by the program’s imple-
mentation compared to pricing in Canada and Australia. METHODS: Nationwide
drug distribution data and drug prices for the Brazilian government’s antiretroviral
access program were obtained for 2010 from the Ministry of Health data. Drug
prices for each drug were converted to daily dosage costs in US dollars. Comparable
government drug prices were obtained for Ontario, Canada and Australia. The
Brazilian, Canadian, and Australian unit drug costs were multiplied by the distri-
bution rates in Brazil to calculate and compare the cost of the Brazilian 2010 drug
distribution using the Brazilian and Canadian/Australian pricing rates. Any cost
savings to the Brazilian government were also calculated. The savings calculation
assumes that the Brazilian government has paid for all of the drugs distributed
regardless of patient utilization rates. Sensitivity analysis was conducted on the
distribution rates, pricing, and utilization rates. RESULTS: The Brazilian govern-
ment saved $448.1 million USD in and $403.1 million USD 2010 versus Canada and
Australia, respectively through its pricing program. The total cost of the drugs
distributed was $1.94 billion with the Brazilian pricing. This compares to $2.37bil-
lion and $2.41 billion dollars using Canadian and Australian pricing rates, respec-
tively. Sensitivity analysis found the results to be stable. CONCLUSIONS: Signifi-
cant costs savings have been realized by the Brazilian government through its drug
pricing program. These costs savings should be included as part of any analysis of
the overall impact of the program.
PIN103
A COMPARISON OF INVESTMENTS FOR DIFFERENT PREVENTION PROGRAMS:
RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS VERSUS HUMAN PAPILLOMA
VACCINE
Roggeri D1, Sambrook R2, Lozano-Ortega G3, Gooch K4, Soro M5
1ProCure Solutions Sas, Nembro, BG, Italy, 2Oxford Outcomes Ltd., Vancouver, BC, Canada,
3Oxford Outcomes, Vancouver, BC, Canada, 4Abbott Laboratories, Abbott Park, IL, USA, 5Abbott
Italia Srl, ROMA, RM, Italy
OBJECTIVES: Childhood prevention programs are important and imperative public
health initiatives. However, prevention programs are often associated with consid-
erable investments. This budget impact analysis was undertaken to position the
Italian investment for a program to prevent respiratory syncytial virus (RSV) con-
sequences in high-risk infants using palivizumab. This prevention program is com-
pared to an existing immunization program in the Lombardy region of Italy: Hu-
man Papillomavirus Vaccine [Types 6, 11, 16, 18] (HPV), considered standard of
care. METHODS: Two budget impact models were developed to assess the impact
of two different programs on Regional Health Service (RHS) expenditure: the budget
impact of RSV prophylaxis program was compared with a non-prophylaxis pro-
gram, while the budget impact of HPV active prophylaxis was compared with a
non-prophylaxis approach. Only direct costs based on disease prevalence, and
program efficacy were included. The model includes RSV prophylaxis administra-
tion costs, RSV-related resource consumption (visits, long term sequelae) and RSV
hospitalization over one year; for HPV prevention program, one year prophylaxis
was assessed against 5 years disease costs due to the low incidence of HPV related
disease in 1 year. Eligible subjects were preterm and high-risk infants (as estab-
lished by national guidelines) for RVS program and all 12-year-old girls cohort for
HPV program. RESULTS: RSV prophylaxis expenditure was estimated at
€11,577,776 in the prophylaxis program arm versus €5,206,534 in the ‘without pro-
phylaxis program’ arm, while for HPV prevention program, vaccination program
expenditure (including vaccine cost) would be 13,068,025€ vs. 356,385€ in no-vac-
cine arm. The net budgetary impact was calculated at €6.4 million for RSV vs. €12.7
million for HPV vaccination. CONCLUSIONS: Considering the RHS perspective, the
budget impact of palivizumab had lower program costs and higher disease cost
offsets vs. HPV vaccination program, positioning its economic value well within the
parameters of cost-effective childhood prevention programs.
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OBJECTIVES: To investigate whether patient reported outcomes could detect dif-
ferences between H1N1 and seasonal influenza vaccinations on resource utilisa-
tion and time off work over a 26 week follow up period. METHODS: In this evalua-
tion, PROBE methodology consisting of a web-based system supplemented by
telephone reporting was used to collect naturalistic data from people who had
received an influenza vaccination during 2009-2010 season. People were recruited
through media advertising and awareness campaigns in public places and work
(West of Scotland). Data collection on day of immunisation, after 3 days, 8 days, 6
weeks, 12 weeks and 26 weeks. Data included baseline demographics, any side
effects following vaccination including the duration/ resource use and time off
work. RESULTS: A total of 1103 vaccine recipients participated in the evaluation.
Overall, 42% of respondents reported experiencing any side effect after vaccination
(excluding pain/discomfort at site of injection) with more people reporting a side
effect with H1N1 vaccination (45% versus 26% seasonal flu vaccination versus 42%
receiving both vaccines p0.001). However, there was no significant difference in
health service utilisation between the groups – 5.2% H1N1, 2.3% Seasonal, 5.5% both
vaccines p0.468. 4 (0.6%) people in the H1N1 only group received hospital treat-
ment, 1 (0.8%) in the seasonal only group and 2 (0.9%) receiving both vaccines. Time
off work (absenteeism), in relation to flu like symptoms, also showed no significant
difference between the groups – 1.7% H1N1, 1.9% Seasonal, 3.4% both vaccines
p0.486. CONCLUSIONS: This evaluation shows that the PROBE methodology
quickly and simply captured patient reported outcome information on resource
utilisation and absenteeism in a vaccinated population. People receiving the H1N1
vaccination alone were more likely to experience side effects than seasonal influ-
enza vaccination alone but this did not lead to a significant increase in resource
utilisation or time off work.
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